17beta-Estradiol replacement improves renal function and pathology associated with diabetic nephropathy

Area of Science:

• Endocrinology
• Nephrology
• Diabetology

Background:

• Diabetes mellitus is a global health concern, leading to significant complications like diabetic nephropathy.
• The protective role of female gender in mitigating diabetes complications appears diminished, with equal incidence observed in both sexes.
• Estrogen's influence on kidney health, particularly in the context of diabetes, warrants further investigation.

Purpose of the Study:

• To investigate the impact of estrogen deficiency, induced by ovariectomy (OVX), on renal function and pathology in a rat model of diabetes.
• To evaluate the renoprotective effects of 17beta-estradiol (E2) replacement in diabetic rats with and without estrogen deficiency.

Main Methods:

• Induction of diabetes using streptozotocin (STZ) in female rats.
• Surgical ovariectomy (OVX) to induce estrogen deficiency, with subsequent 17beta-estradiol (E2) replacement in specific groups.
• Assessment of renal function through urine albumin excretion (UAE) and creatinine clearance (CrCl) over 12 weeks.
• Histopathological evaluation of glomerulosclerosis (GSI) and tubulointerstitial fibrosis (TIFI), alongside transforming growth factor-beta (TGF-beta) protein expression analysis.

Main Results:

• Diabetes significantly increased UAE, GSI, TIFI, and TGF-beta expression, while decreasing CrCl.
• Estrogen deficiency (OVX) in diabetic rats further worsened these renal parameters.
• 17beta-estradiol replacement in OVX diabetic rats significantly attenuated the decline in renal function and pathology.

Conclusions:

• Estrogen deficiency intensifies renal disease severity in a diabetic animal model.
• 17beta-estradiol replacement therapy exhibits renoprotective properties by mitigating diabetes-associated renal dysfunction and damage.